Details of the Drug Reposition

General Information of This Drug (ID: DMH5LFR)

Drug Name
ALXN6000   DMH5LFR
Synonyms Samalizumab
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1/2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT00648739) Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM. U.S. National Institutes of Health.